[Management of multiple myeloma-related bone disease].
Multiple myeloma is still incurable malignant neoplasm of plasma cells, which is characterized by the presence of osteolytic bone disease, the latter resulting from increased osteoclast function accompanied by decreased osteoblast activity. Myeloma bone disease is associated with the risk of skeletal events, such as pathologic fractures, spinal cord compression, or a need of palliative bone treatment or surgery, and may be related to decreased survival. In this review article, the results of the studies analyzing treatment options for myeloma bone disease and its complications are summarized. In addition, up-to-date guidelines based on those results are presented. Indications for therapy with bisphosphonates, the route of their administration and the optimal treatment duration are presented. Moreover, methods used for management of myeloma bone disease complications are discussed, including local radiotherapy, kyphoplasty and vertebroplasty.
Artur
A
Jurczyszyn
Sebastian
S
Grosicki
Maciej R
MR
Czerniuk
Rafał
R
Morga
Krzysztof
K
Małecki
Aleksander B
AB
Skotnicki
D001847:Bone Diseases / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications*; D010006:Osteoblasts / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism; D013117:Spinal Cord Compression / Q000209:etiology
D004164:Diphosphonates